Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 04, 2015 4:01 AM ET

Pharmaceuticals

Company Overview of Essentialis, Inc.

Company Overview

Essentialis, Inc., a pharmaceutical company, engages in the development of medicines for the treatment of cardiovascular and metabolic diseases. It offers DCCR, a once-a-day tablet formulation for patients with very high triglycerides. The company was founded in 2003 and is based in San Diego, California.

9393 Towne Centre Drive

Suite 200

San Diego, CA 92121

United States

Founded in 2003

Phone:

858-964-5013

Fax:

858-964-5028

Key Executives for Essentialis, Inc.

Founder and Advisor
Director of Clinical Operations
Senior Director of Chemistry
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Essentialis, Inc. Key Developments

Essentialis Presents Results From the First Phase of Clinical Study PC025 Evaluating DCCR in the Treatment of Prader-Willi Syndrome at ACMG Annual Clinical Genetic Meeting

Essentialis announced that the principal investigator for clinical study PC025 will be presenting a summary of the results of the first phase of clinical study PC025 at the Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics. Clinical study PC025 is designed to evaluate the safety and efficacy of DCCR in obese Prader-Willi syndrome (PWS) patients. PWS is a complex multi-system genetic disorder affecting 1:10,000 to 1:30,000 males and females and people of all ethnicities equally. Initial clinical features of PWS include hypotonia leading to poor suck, difficulty feeding and failure to thrive in infancy. Low muscle mass and low resting energy expenditure is present throughout life. The central neurological defect of the disease causes PWS patients to sense that they are starving and signals them to further conserve energy and to significantly increase their caloric intake resulting in hyperphagia, morbid obesity, and an increased incidence of diabetes. Developmental delay/mild intellectual disability, growth hormone deficiency, behavioral problems, including aggressive and threatening behaviors, mental illness and neuroendocrine abnormalities are frequently observed. Clinical study PC025, a randomized withdrawal study, enrolled 13 obese, genetically confirmed, PWS patients between the ages of 10 and 22. The first phase involved 10 weeks of open label treatment during which patients were titrated up on dose and then stably treated for the remainder of the 10 weeks. This is followed by a 4 week double-blind, placebo-controlled treatment phase. The endpoints in the first phase included changes in body composition (body fat, lean body mass, lean body mass/fat mass ratio), changes in hyperphagia, changes in behavior, and safety. Five female and 8 male patients were randomized in the study. On average, they were 16 years old, weighed 89 kg, had 52% body fat, and moderate hyperphagia. Six of the 13 patients in the study were treated with growth hormone at baseline and continued that treatment throughout the study. Nearly all were cared for in the home and there was no per protocol change in caloric intake or exercise.

Essentialis, Inc. Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome

Essentialis, Inc. announced the receipt of a grant from the Foundation for Prader-Willi Research to support clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets in obese Prader-Willi syndrome patients. The clinical study is being conducted at the University of California, Irvine under the direction of Dr. Virginia Kimonis.

Similar Private Companies By Industry

Company Name Region
MimiVax, LLC United States
NEXTherapeutics, Inc. United States
Roex Inc. United States
ProlX Pharmaceuticals Corporation United States
Great Southern Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Essentialis, Inc., please visit www.essentialistherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.